Investment Rating - The investment rating for By-health is maintained as BUY with a target price of RMB15.37, indicating a potential upside of 31% from the closing price of RMB11.71 as of August 9, 2024 [7][8]. Core Insights - By-health's revenue and net profit have declined significantly in the first half of 2024, with revenue at RMB4,610 million (-17.6% year-on-year) and attributable net profit at RMB890 million (-42.3% year-on-year) [3][4]. - The decline is attributed to a high base from the previous year and challenges in the company's omni-channel strategy, which includes a diverse product lineup facing competition across various e-commerce platforms [3][4]. - The company plans to focus on its main brand and Life-Space, consolidating offline sales channels and enhancing product differentiation to expand into lower-tier markets [3][4]. Financial Performance Summary - For 1H24, By-health's gross profit margin (GPM) fell to 68.6%, down 1.8 percentage points year-on-year, with a notable decline in the second quarter to 66.8% [4]. - The sales expense ratio increased to 39.5% in 1H24, primarily due to higher brand promotion investments and increased platform expenses [4]. - The company has revised its earnings forecasts downward, estimating EPS for 2024, 2025, and 2026 at RMB0.70, RMB0.83, and RMB0.97 respectively [5][6]. Revenue and Profit Forecasts - Revenue projections for By-health are as follows: RMB8,447 million for 2024, RMB9,268 million for 2025, and RMB10,032 million for 2026, reflecting a decline in 2024 followed by growth in subsequent years [6]. - Net profit estimates are projected at RMB1,188 million for 2024, RMB1,419 million for 2025, and RMB1,648 million for 2026, indicating a recovery trend after a significant drop in 2024 [6]. Market Position and Strategy - By-health continues to strengthen its brand presence despite facing short-term revenue adjustments due to changing consumer sentiment and increased competition [4]. - The company is focused on improving operational quality and refining its strategy to adapt to the evolving market landscape [4].

Investment Rating - The investment rating for Tasly Pharmaceutical is maintained at OVERWEIGHT, with a target price of RMB17.30, indicating a potential upside of 25% from the closing price of RMB13.85 as of August 9, 2024 [3][10][30]. Core Insights - The controlling shareholder of Tasly, Tasly Group, plans to transfer 28% of its share capital (approximately 418 million shares) to CR Sanjiu for a total consideration of around RMB6,212 million. This acquisition is expected to enhance CR Sanjiu's industrial chain and leverage Tasly's expertise in traditional Chinese medicine and innovative pharmaceuticals [3][4]. - Tasly is projected to achieve attributable net profits of RMB1.18 billion, RMB1.31 billion, and RMB1.46 billion for the years 2024, 2025, and 2026, respectively, reflecting year-on-year growth rates of 10%, 11%, and 11% [3][4]. - The report anticipates stable business fundamentals for Tasly in 2024, with steady growth in its traditional Chinese medicine segment and a rally in sales volume for chemical drugs driven by the VBP program [5][6]. Summary by Sections Business Overview - Tasly is recognized as a leader in traditional Chinese medicine prescription drugs and has a strong R&D pipeline with 98 products in development. The company has developed blockbuster products such as Danshen and Yangxue Qingnao [4][5]. Financial Projections - Revenue is expected to grow from RMB8,593 million in 2022 to RMB10,506 million by 2026, with net profit projected to increase from a loss of RMB256.51 million in 2022 to RMB1,460 million in 2026 [8][15]. - The earnings per share (EPS) is forecasted to rise from a loss of RMB0.17 in 2022 to RMB0.98 in 2026 [8][15]. R&D and Innovation - Tasly has consistently invested in R&D, with annual expenses ranging from RMB600 million to RMB900 million since 2018, representing an R&D expense ratio of 5-10%. The company has independently developed over 20 novel TCM products, with several projects expected to submit NDAs starting in 2024-2025 [6][4]. Market Position - The acquisition by CR Sanjiu is expected to reshape Tasly's competitive landscape, integrating management systems and potentially adjusting business practices from 2025 onwards [4][5].

Investment Rating - The investment rating for Wens Foodstuffs is "BUY" with a target price of RMB25.53, indicating a potential upside of 29% from the closing price of RMB19.78 as of August 12, 2024 [2][7]. Core Views - Wens Foodstuffs has experienced a significant rise in meat pig selling prices, with the average price reaching RMB18.95/kg in July, which is above the industry average. The estimated per-head profit for meat pigs is nearly RMB600 [2][3]. - The report anticipates buoyant demand for pigs and broilers in the second half of 2024 due to tight supply dynamics and an approaching peak consumption season, which is expected to sustain earnings growth for Wens [2][4]. - The financial projections for Wens indicate a net profit of RMB10.0 billion in 2024, increasing to RMB13.4 billion in 2025, and RMB13.1 billion in 2026, with a book value per share (BVPS) of RMB6.48, RMB8.29, and RMB10.16 respectively [2][5]. Summary by Sections Financial Performance - Revenue is projected to grow from RMB89.92 billion in 2023 to RMB104.68 billion in 2024, and further to RMB125.67 billion in 2025 [5]. - The net profit is expected to recover from a loss of RMB6.39 billion in 2023 to RMB10.04 billion in 2024, and reach RMB13.36 billion in 2025 [5]. - The diluted EPS is forecasted to improve from -0.96 in 2023 to 1.51 in 2024, and 2.01 in 2025 [5]. Market Dynamics - The report highlights a potential contraction in hog supply in the second half of 2024, which is expected to drive up prices and enhance profitability for Wens [2][4]. - The demand for yellow-feather broilers is projected to increase due to early-stage destocking and seasonal consumption patterns, contributing to a favorable pricing environment [2][4]. Competitive Position - Wens Foodstuffs is noted for its solid cost advantage in hog breeding, which is expected to further enhance its per-head profit margins [2][4]. - The company is likely to continue making progress in breeding, production, and management, which will contribute to a steady decline in breeding costs [3][4].

Equity Research Report Jafron Biomedical (300529 CH) Earnings Grew Strongly in 2024 Huatai ResearchInterim Results Review 13 August 2024 | China (Mainland)Medical Devices Earnings growth continued to pace up in 2Q24; maintain BUY Jafron Biomedical (Jafron) registered 1H24 revenue/attributable net profit (NP) of RMB1,496/553mn (up 47.8/99.1% yoy) and 2Q24 revenue/attributable NP of RMB751/268mn (up 70.9/230.6% yoy), which further picked up from the growth rates in 1Q24 (revenue/attributable NP: up 30/44.9% y ...

Investment Rating - The investment rating for Canmax Technologies is maintained at OVERWEIGHT with a target price of RMB 17.94, reflecting an expected upside of 8% from the closing price of RMB 16.59 as of August 9, 2024 [7][8]. Core Insights - Canmax Technologies reported a significant decline in its financial performance for 1H24, with attributable net profit down 39.26% year-on-year to RMB 835 million, and revenue down 44.09% year-on-year to RMB 3,713 million [2][3]. - The decline in revenue is primarily attributed to a substantial decrease in lithium ore prices, with the average selling price of lithium hydroxide falling 73.8% year-on-year to RMB 92,300 per tonne [3][5]. - Despite the challenges, Canmax's revenue decline was less severe than the drop in lithium ore prices, largely due to capacity expansion efforts [3]. Financial Performance - For 1H24, Canmax's revenue from lithium-ion battery materials decreased by 47.08% year-on-year to RMB 3,316 million, with a gross profit margin of 17.91%, down 12.59 percentage points year-on-year [3]. - The company's projected book value per share (BVPS) for 2024, 2025, and 2026 is RMB 15.74, RMB 17.07, and RMB 19.24 respectively [2]. - The financial outlook shows a recovery in revenue expected in 2025 and 2026, with projected revenues of RMB 11,602 million and RMB 17,671 million respectively [6]. Industry Dynamics - The lithium ore market is currently experiencing oversupply, leading to continued price declines in 1H24, although there are signs of potential capacity cuts from major producers [5]. - The report suggests that while lithium ore prices are expected to remain on a downward trend, the pace of supply-side de-capacity should be monitored as it may lead to improved supply-demand dynamics in the future [5].

9 August 2024 | 10:36PM HKT _ Focus Media Information Tech (002027.SZ) 2Q24 Review: Accelerating ad revenue with 5% dividend yield; Buy Buy 0007.SZ 12mPrie Target: Rmb7.50 Prie: Rmb5.78 Upside: 9.8% We maintain our Buy rating on Focus Media while raise our 12-m TP to Rmb7.5 (30% upside) post its strong 2Q24 results (see our note) and mgmt call.The stock has dropped 3% post results despite the headline revenue beat (+10% yoy vs. ÍGSe of +4%, Visible Alpha Consensus of +4%), NI beat (+13% yoy, 9% ahead of GSe ...

Investment Rating - Maintain BUY rating for Shenzhen MTC with a target price of RMB 6 90 [2] Core Views - Shenzhen MTC reported robust 1H24 revenue and net profit growth with revenue reaching RMB 9 520mn (+23 07% yoy) and net profit at RMB 911mn (+24 04% yoy) [2] - The company's dual growth driver strategy focusing on multimedia and LED businesses is effective with LED industry chain revenue reaching RMB 2 584mn (+29 4% yoy) [2][4] - TV output recovery and increased market share in COB direct-view display business contributed to the strong performance [3][4] Financial Performance - 1H24 revenue from multimedia audio-visual products and operation services was RMB 6 936mn (+21% yoy) with over 5 4mn units of smart display terminals shipped [3] - LED business revenue was driven by product-mix upgrades and increased penetration of Mini LED COB direct-view display products (1H24 revenue: RMB 432mn) [4] - Gross profit margin (GPM) for 2Q24 improved by 0 1pp yoy due to stable TV panel prices and higher contributions from high-margin LED products [5] Future Projections - Revenue is expected to grow to RMB 20 762mn in 2024E (+20 94% yoy) and RMB 25 308mn in 2026E (+9 28% yoy) [6] - Net profit is projected to increase to RMB 2 094mn in 2024E (+31 86% yoy) and RMB 2 678mn in 2026E (+10 64% yoy) [6] - EPS forecasts for 2024E/2025E/2026E are maintained at RMB 0 46/0 53/0 59 [2] Valuation - The stock is valued at 15x 2024E PE above the Wind consensus-based peers' average of 11 7x [2] - Potential upside of 46% based on the target price of RMB 6 90 and closing price of RMB 4 71 as of 7 Aug [8]

Investment Rating - The investment rating for Bank of Hangzhou is maintained at OVERWEIGHT with a target price of RMB14.42, indicating a potential upside of 12% from the closing price of RMB12.93 as of 7 August 2024 [6][28]. Core Insights - In 1H24, Bank of Hangzhou experienced a revenue growth of 5.4% year-on-year and attributable net profits increased by 20.1% year-on-year, reflecting a strong performance with stable asset quality [1][2]. - The bank's total assets, loans, and deposits grew by 13.8%, 16.5%, and 13.7% year-on-year respectively, with significant increases in loan and deposit amounts compared to the previous year [2]. - The non-performing loan (NPL) ratio remained low at 0.76%, with a provision coverage ratio of 545%, indicating strong risk management capabilities [3][4]. Financial Projections - Projected earnings per share (EPS) for 2024, 2025, and 2026 are RMB2.91, RMB3.47, and RMB4.13 respectively, with a book value per share (BVPS) of RMB18.02 for 2024 [1][5]. - Revenue is expected to grow from RMB36.6 billion in 2024 to RMB41.8 billion in 2026, while net profit attributable to the parent is projected to rise from RMB17.3 billion in 2024 to RMB24.5 billion in 2026 [11][12]. Market Position and Strategy - Bank of Hangzhou operates in economically vibrant regions and focuses on corporate loans, particularly to government credits and state-owned enterprises, which supports its growth strategy [2][4]. - The bank has established a diversified shareholder base and has been a pioneer in tech-innovation banking, enhancing its competitive edge [4].

Investment Rating - The report assigns a Buy rating to Kweichow Moutai with a 12-month price target of Rmb2,098 [3][4] Core Investment Thesis - Kweichow Moutai is the largest player in the China spirits industry with a 20% value share in 2022 [3] - The company benefits from strong fundamentals, high visibility, and upside from channel reforms [3] - Near-term earnings drivers include wholesale and direct sales growth, product portfolio enhancement, and price hikes [3] - Long-term growth is supported by supply-demand gap, market-driven pricing system, and growth of Moutai-flavor spirits [3] Financial Performance and Estimates - 2Q24 revenue was Rmb37.0bn, up 17% YoY, with net profit of Rmb17.6bn, up 16.1% YoY [35][55] - Moutai Spirits revenue grew 13% YoY to Rmb28.9bn, while Series spirits revenue accelerated to 43% YoY at Rmb7.2bn [35][36] - i-Moutai generated Rmb4.91bn in spirits sales in 2Q24, up 11% YoY, exceeding expectations [55] - The company aims for a 75% dividend payout ratio for 2024-26, implying total shareholder return of Rmb219bn [56] Valuation and Price Target - The 12-month price target of Rmb2,098 is based on a 29.4x 2026E P/E, discounted back to 2024E year-end using a 9.8% CoE [4] - The target P/E includes a 40% premium for Moutai's leading position in China's spirits industry and strong returns profile [4] - Moutai is trading at 21x/18x 2024E/2025E P/Es with a 12% earnings CAGR in 2024E-26E [63] Product and Channel Performance - Wholesale channel sales grew 27% YoY in 2Q24, supported by a price hike in November 2023 [55] - Direct sales grew 6% YoY in 2Q24, contributing 40% of total spirits sales [55][59] - i-Moutai contributed 14% of total sales in 2Q24, with 531k bottles released in July, down 60% YoY [60] Market Trends and Pricing - Feitian Moutai's wholesale price increased by Rmb180 for original case and Rmb130 for unpacked bottles in July [78] - Channel inventory stands below 1 month, with shipments expected to increase for the Mid-Autumn Festival [78] - Non-standard SKUs like Jingpin and Zodiac Moutai maintain decent channel profitability [79] Production and Supply - Base spirits production volume declined YoY in 1H24, with Moutai base spirits down 12.3% and Series base spirits down 5.4% [60] - The company has implemented active shipment controls, particularly for Moutai 1935 and Zodiac (500ml) [60]

Investment Rating - The investment rating for Foxconn Industrial Internet is maintained as BUY with a target price of RMB30.00 [1][4][6] Core Insights - Foxconn Industrial Internet (FII) reported record high revenue and net profit for 1H24, driven by strong demand for AI servers, with revenue reaching RMB266,091 million and attributable net profit at RMB8,739 million, reflecting year-on-year increases of 28.7% and 22.0% respectively [1][2] - The company is positioned strategically in the digital economy and AI development, enhancing its presence in cloud computing and network communications through advanced technology and capacity expansion [1][2] - FII's AI server revenue has multiplied, indicating a rapid growth phase, and the company expects further earnings growth from new-generation servers due to deep cooperation with leading global clients [2][3] Financial Performance - For 1H24, FII's revenue from cloud computing and AI products showed robust growth, with significant contributions from its cloud service provider (CSP) segment [2] - The company maintains its EPS estimates for 2024, 2025, and 2026 at RMB1.25, RMB1.46, and RMB1.63 respectively, and values the stock at 24x 2024E PE, which is above the average of its peers [4][6] - FII's revenue projections for the upcoming years are RMB538,810 million for 2024E, RMB613,666 million for 2025E, and RMB665,779 million for 2026E, with net profit estimates of RMB24,809 million, RMB28,976 million, and RMB32,441 million respectively [5][6] Recent Developments - FII has demonstrated confidence in its sustainable development through a recent share buyback proposal and a capital increase of RMB214 million aimed at accelerating project construction [3] - The capital expenditures of major tech companies like Microsoft, Google, Amazon, and Meta have increased significantly, indicating sustained optimism for future investments in AI computing infrastructure, which benefits FII's cloud computing business [3]